DCA Docosanoic C22 LMO Modifier
DCA C22, also known as docosanoic acid or behenic acid, is a 22-carbon saturated fatty acid used as a lipid modification for therapeutic oligonucleotides. Conjugation of a C22 lipid increases the hydrophobic character of DNA or RNA molecules and is frequently investigated as a strategy to improve systemic exposure, plasma protein binding, tissue distribution, and cellular uptake.
Long-chain fatty acid conjugation has become an important approach in the development of antisense oligonucleotides (ASOs), siRNA, splice-switching oligonucleotides, aptamers, and other nucleic acid therapeutics. The lipid moiety associates reversibly with serum albumin and other circulating proteins, which can reduce renal clearance and prolong circulation time. These properties may improve delivery to target tissues while maintaining bioavailability.
Compared with shorter fatty acids such as palmitic acid (C16) or stearic acid (C18), C22 docosanoic acid provides a longer hydrophobic chain that may further enhance protein association and alter biodistribution. The optimal lipid conjugate depends on the therapeutic target, administration route, and desired pharmacokinetic profile.
Bio-Synthesis offers custom DCA C22 lipid-modified oligonucleotides for a variety of nucleic acid platforms, including:
- DNA oligonucleotides
- RNA oligonucleotides
- siRNA
- Antisense oligonucleotides (ASOs)
- Gapmers
- Splice-switching oligonucleotides
- Aptamers
- Custom therapeutic oligonucleotides
DCA C22 lipid conjugation is frequently combined with additional chemistries such as:
- Phosphorothioate backbones
- LNA/BNA modifications
- 2′-O-Methyl RNA
- 2′-Fluoro RNA
- 2′-MOE RNA
- PEG linkers
- Cleavable linkers
- GalNAc targeting ligands
Typical research applications include:
- Therapeutic oligonucleotide delivery
- Lipid-conjugated siRNA
- Antisense oligonucleotide optimization
- Albumin-binding strategies
- Pharmacokinetic optimization
- Tissue targeting studies
- Drug delivery research
- In vivo efficacy evaluation
Typical Specifications
| Property |
Specification |
| Modification |
DCA C22 (Docosanoic / Behenic Acid) |
| Chemical Class |
Long-chain saturated fatty acid (lipid conjugate) |
| Carbon Chain Length |
C22 |
| Chemical Name |
Docosanoic acid (Behenic acid) |
| Typical Placement |
5′ or 3′ terminus |
| Compatible Oligonucleotides |
DNA, RNA, siRNA, ASOs, aptamers, splice-switching oligonucleotides |
| Primary Benefits |
Enhanced hydrophobicity, plasma protein binding, tissue distribution, and pharmacokinetic optimization |
| Typical Applications |
Therapeutic oligonucleotide delivery, lipid conjugation, in vivo studies, albumin-binding strategies, drug delivery research |
Product Information
DCA Docosanoic C22 LMO Modifier
-20°C To -70°C
Oligonucleotides are stable in solution at 4°C for up to 2 weeks. Properly reconstituted material stored at -20°C should be stable for at least 6 months. Dried DNA (when kept at 20°C) in a nuclease-free environment should be stable for years.
References/Citations:
- Juliano R. The delivery of therapeutic oligonucleotides. Nucleic Acids Research. 2016;44(14):6518-6548.
- Crooke ST, Liang XH, Baker BF, Crooke RM. Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery. 2021;20:427-453.
- Godfrey C, et al. Lipid-conjugated oligonucleotides for therapeutic delivery. Advanced Drug Delivery Reviews. 2023.
- Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery. 2020;19:673-694.
No Product Found